Pharma BD Deal Intelligence

Pfizer Inc. / Medivation Inc.

2016 · Acquisition/Merger · $14.0B · Complete

The Street Said

Strongly positive — critic reaction at announcement

History Says

Worked — the deal delivered on its rationale

CALLED IT — OFF BY 11

Full analysis, sources & comparables →

The coverage arc

Aug 22, 2016 STAT News Neutral

Pfizer buying Medivation in deal valued at about $14 billion.

Aug 30, 2016 Medivation SC 14D-9 Neutral

Pfizer and its acquisition subsidiary filed a Tender Offer Statement on Schedule TO and Medivation filed a Solicitation/Recommendation Statement on Schedule…

Source summaries from our enrichment pipeline; follow links for originals.

All 4 sources with sentiment breakdown →

Pfizer acquired Medivation for approximately $14 billion ($81.50 per share in cash), gaining full ownership of XTANDI (enzalutamide) for prostate cancer and the Phase III PARP inhibitor talazoparib, strengthening Pfizer's oncology portfolio.

Key facts

Announced Aug 22, 2016
Closed Sep 28, 2016
Deal value $14.0B
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Prostate Cancer, Breast Cancer (BRCA-mutated)
Key assets XTANDI (enzalutamide), talazoparib (PARP inhibitor), pidilizumab (immuno-oncology)
Mechanism Androgen receptor inhibitor, PARP inhibitor

Related deals — scored

Deal	Year	Value	Outcome
Pfizer Inc. / Medivation Inc. (this deal)	2016	$14.0B	86
Pfizer Inc. / BioNTech SE	2020	$748M	100
Pfizer Inc. / FoldRx Pharmaceuticals	2010	—	99
Pfizer Inc. / Wyeth	2009	$68.0B	86
Pfizer Inc. / Warner-Lambert Company	2000	$90.0B	83
Pfizer Inc. / Arvinas, Inc.	2021	$2.4B	77
Pfizer Inc. / Seagen Inc.	2023	$43.0B	77

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2016 deals · Pfizer Inc. deals · Oncology deals